How Pelosi’s K Street Gang Profited Off Coronavirus
https://investigativeresearchcenter.org/how-pelosis-k-street-gang-profited-off-coronavirus/
BIG PHARMA
On March 5, 2020, Congress passed, “The Coronavirus Preparedness and Response Supplemental Appropriations Act 2020.”
Politico made it known that the drug industry “got its way” with that legislation and “successfully blocked attempts this week to include language in the $8.3 billion emergency coronavirus spending bill that would have threatened intellectual property rights for any vaccines and treatments the government decides are priced unfairly.” Journalist Sarah Karlin-Smith notes that they “not only killed” the undesired provision, but they actually had favorable language added.
Disclosures records from 2018-2020 show that the following Pelosi staffers had recently lobbied on behalf of pharmaceutical interests. The dollars received for activities listed is from their own disclosure forms, which reveal “good faith” estimates of their firm’s income related to the client dating back to the beginning of Pelosi’s current term as speaker of the House of Representatives.
Nadeam Elshami, former Pelosi chief of staff.
▪ Lobbied for Walgreen Co. on Drug Pricing Issues, including on “H.R. 748 CARES Act – Issues related to COVID-19 relief” in 2020 Q1. ($680,000)
▪ Represented Wilmer Hale on behalf of Purdue Pharma by “monitoring legislative and regulatory activities impacting the pharmaceutical industry.” ($350,000)
▪ Represented AbbVie on “issues related to pharmaceutical manufacturing” and “patent reform,” including on “H.R. 748 CARES Act – Issues related to COVID-19 relief in 2020 Q1. ($260,000)
▪ Lobbied for Johnson & Johnson on prescription pricing; HR 748 CARES Act, Issues related to COVID-19 treatment in 2020 Q1. ($420,000)
▪ Lobbied for Amgen on prescription price issues. ($350,000)
▪ Lobbied for Lilly USA, LCC on pharmaceutical industry issues, including on “H.R. 748 CARES Act – Issues related to COVID-19 relief” in 2020 Q1. ($80,000)
▪ Lobbied for Novartis on pharmaceutical pricing, including on “H.R. 748 CARES Act – Issues related to COVID-19 relief” in 2020 Q1. ($220,000)
Dean Aguillen, former Pelosi senior advisor.
▪ Lobbied for PhRMA on “general prescription drug affordability and access.” ($230,000)
▪ Lobbied for Pfizer on “issues related to drug pricing” and “general issues related to the pharmaceutical industry.” ($720,000)
Anne MacMillan, former Pelosi senior policy advisor
▪ Lobbied for GlaxoSmithKline to “monitor and educate policymakers” on pharmaceutical industry issues, including “educat[ing] Members on efforts to develop a potential vaccine for COVID-19 in 2020 Q1. ($360,000)